As a Principal Consultant in Data Strategy, my role encompasses designing and executing comprehensive data strategies for Zifo's diverse clientele (e.g. Biotech, Large Pharma, and Consumer Health). Here I deliver data-driven transformation initiatives that innovatively align data capabilities with our clients' business objectives, helping them to maximize both data value and business impact.My approach involves an in-depth journey with clients, tackling their unique business challenges and objectives, evaluating their current (AS-IS) digital and data maturity, and envisioning their data-driven transformation roadmaps.Core responsibilities include:• Formulating and executing Zifo's proprietary data strategy framework.• Developing an extensive range of data-centric consulting services, with an emphasis on AI-readiness. • Creating innovative concepts and governance model for the integration of GenAI in organizational structures.

Since joining Molecular Health in 2007, I was responsible for many of the concepts and inventions that underlie the company's DATAOME technology platform. My passion for the clinical practicalities and molecular challenges facing precision medicine is focused on the real-time needs of oncologists, pathologists, and above all, patients. I am a long-time proponent of the need for a more holistic, evidence-based approach to patient care that includes the integrated analysis of both patient intrinsic (e.g. tumor genome, personal genome) and patient extrinsic (e.g co-medication) data. This focus and responsibility has thus far led to the development of clinical decision support technologies (e.g. MH EFFECT and MH GUIDE) and the discovery of several novel predictive biomarkers (e.g. Cancer Cell. 2015 Nov 9;28(5):610-622). My current innovation focus includes the development of automated strategies for the clinical interpretation of clinico-molecular data, evidence capture using Deep Learning methods, biomarker discovery, treatment/trial prioritization and predictive drug safety solutions. While at MH, I authored several patents and peer-reviewed publications across each of these themes (see publication list below (2009-2022) for further reference). I currently maintain an active advisory role to the company.

Extra Virgin Olive Oil (EVOO) has long been recognized for its health promoting properties. Ancient Greek doctors such as Hippocrates and Dioscurides described more than 60 different therapeutic uses of olive oil, including the treatment of inflammation – one of the most common features of chronic diseases such as cancer, cardiovascular disease and neurological disorders (e.g. Alzheimers). They also believed it to be a natural elixir that could stave off illness and promote human longevity. Today, thanks to advances in modern science, we have made great strides in understanding the reasons behind this ancient wisdom. Over the past couple of decades, scientists have isolated and characterized many of the natural phytonutrients believed to be responsible for many of EVOO’s health-related benefits. Together, these phytonutrients provide the foundations of the Mediterranean diet.I founded OLIFE.bio as a personal "Trojan Horse" into the world of Precision Health. My initial goal was to produce the purest EVOO, rich in natural bioactive compounds. But what began as a hobby, quickly evolved into a project of passion and purpose. The passion stems from the magnificent olive trees and the land and traditions that nurture them. They grow in a micro-climate and soil that has been generous to both tree and farmer since ancient times. The purpose on the other hand, stems as a personal response to the negative health effects of ultra processed foods - culpable for the increasing rates of chronic disease and ecological collapse the world over. Given that the Peloponnes is not only a region of unspoiled natural beauty, but historically also a place of successful rebellion – it provides the perfect setting to passionately pursue the creation of the purest, premium quality, organic EVOO. Today, the company is run by my wife, whilst I maintain responsibility for the care of the groves and the natural approaches to producing a health promoting olive oil, rich in bioactives.

In this academic role at the DKFZ, I coordinated the National endeavours in Bioinformatics for the National Genome Forschungs Netzwerk, within the Group of Prof. Roland Eils. The goal of this project was to facilitate the maximized utilisation and 'metamorphosis' of data from the NGFN2 initiative into biomedical knowledge. By providing the infrastructure and know-how necessary for this 'data to knowledge' transfer, the Bioinformatics efforts played a key role in ensuring the success of NGFN2 as a whole. The approach followed a concept of both centralized and decentralized data organization, manage­ment, analysis, interpretation and training. In so doing, we not only provided local support for the administration and analysis of experimental data, but also provided a comple­mentary systematic platform with centralized knowledge, tools and resources. In terms of generic organization, SMP Bioinformatics was founded on three distinct, albeit interdependent components. Together, these elements allowed a so-called '3i-approach' to the data to knowledge transformation within the NGFN2 project =>1) Integrate, 2) Interpret and 3) Inform. The associated sub-projects are listed below.Project List:1 - INTEGRATE1.1 Databases for new data types.1.2 Standardisation of clinical data & data management.1.3 Data repository and showcase for NGFN-2.1.4 Data Integration1.5 3D Structural Information for Genomics.2 - INTERPRET2.1 Biomedical Informatics2.2 Comparative and integrative analysis of genomic, transcriptomic and proteomic data.2.3 Method development for enhanced biological interpretation of gene expression data.2.4 Gene Sets2.5 Functional genome annotation3 - INFORM3.1 Development and distribution of data analysis software3.2 Practical Microarray Data Analysis Courses3.3 Methodological Quality and Consulting3.4 Bioinformatic Services and Coordination

Cellzome is a leader in Chemoproteomics, a technology which monitors the interaction of small molecules with their protein targets under close-to-physiological conditions, directly in cells or tissues. Cellzome was founded 2000 as a spin-off of the European Molecular Biology Laboratories (EMBL) and is located on the EMBL campus in Heidelberg, Germany. The company was acquired by GSK in May 2012 and was integrated as fully owned GSK daughter company in GSK’s Platform Technology and Sciences team. Cellzome’s technology Cellzome has pioneered the advancement of chemoproteomics to study the effects of active small molecules on the proteome, the protein content of a cell or tissue, which comprises in excess of 10,000 different proteins. Cellzome applies chemoproteomics in a quantitative manner at various stages in drug discovery and development, from screening to selectivity profiling of drugs in different cell and tissue types. During my time at Cellzome, I lead a team of bioinformaticians in developing a platform dedicated to Target Identification and Discovery. Our most important work helped define a physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway - published in Nature Cell Biology 2004 Feb;6(2):97-105.